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Abstract An attempt was made to compare the usefulness of
determining markers carcinoembryonic antigen (CEA) and
tumor-associated trypsin inhibitor (TATI) in endometrial can-
cer patients in whom recurrence or distant metastasis was
diagnosed in observation after treatment. The study included
316 patients aged 32–81, average age of 61 years, SD=8.72,
with diagnosed endometrial cancer, treated between 1994 and
1995 at the Oncology Center in Warsaw and then under ob-
servation from 4 months to 17 years after completion of treat-
ment. The levels of the markers TATI and CEAwere assessed
from the first five serum samples taken during postoperative
radiotherapy and in the initial period of observation after com-
pleted treatment. Receiver operating characteristic (ROC)
curves were generated, determining the sensitivity and speci-
ficity of both CEA and TATI in patients who experienced
treatment failure, i.e., recurrence and distant metastasis.
Assessing the sensitivity of the marker CEA, it was found that
if in the third sample, i.e., during radiation therapy, the marker
level increased by more than 20 % compared with the first
sample, then recurrence of cancer occurred during the obser-
vation period in 75.9 % of patients and metastatic occurred in
69.7 % of patients. In the evaluation of the marker TATI, it
was found that if the level of TATI between the first and the
third sample increases by 10.6 % from the initial level, then in
84.4 % (sensitivity) of cases, this means the occurrence of
cancer recurrence and in 75.7 % (sensitivity) of cases, the
occurrence of metastasis. The specificity of both markers is
low and not useful diagnostically.
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Introduction
Carcinoembryonic antigen (CEA) was first described in 1956
independently by two groups of researchers—Gold and
Freedman as well as Kleist and Burtin. Initially, the antigen
was determined in patients with colorectal cancer and was
isolated from the intestines of developing fetuses [1, 2]. In
1965, Goldman and Freedman described the relevance of tu-
mor markers and thus initiated the era of discovery of newer
and newer markers that coexist with cancer, reproducing the
phenomenon of proliferation, differentiation, and death of
cancer cells. CEA is considered as one of the markers associ-
ated with the stage of tumor development, and in the assess-
ment of the American Society of Clinical Oncology (ASCO),
it is the most often studied marker. The diagnostic value of the
marker is particularly important in the case of tumors of the
colon and rectum [3, 4].
In most cases, high levels of CEA are present in patients
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5]. CEA is elevated in 19 % of smokers and 3 % of healthy
people and also in pregnant women and alcoholics [6–8].
The first reports of a rise in the level of CEA in patients with
endometrial cancer come from the 1970s. In 1977, German
scientists Anger and Gleissenberger observed an increase in
the concentration of CEA in 38 % of patients with endometrial
cancer, which decreased after completion of treatment [9]. In
the same period, U.S. researchers have demonstrated a correla-
tion between the increase in the level of CEAwith the histolog-
ical type and the clinical progress of endometrial cancer [10].
Tumor-associated trypsin inhibitor (TATI) is a protein
whose concentration in the blood increases in many types of
cancers, both benign and malignant. This inhibitor is
expressed in the cells of solid tumors and an increase of its
level above 20 μg/l in the blood serum, and above 50 μg/l in
urine has a negative prognostic significance in the course of
ovarian, kidney, bladder, colon, biliary tract, and liver cancer.
TATI was first isolated from the urine of patients with ovar-
ian cancer. It is a protein produced in large amounts by ovarian
tumor cells and is included in the group of serine protease
inhibitors Kazal-type 1 (SPINK1) [11–15].
Under physiological conditions, TATI inhibits the activity of
trypsin, contributing positively to the protection of tissue against
its proteolytic effects. However, a negative and synergistic effect
of TATI and trypsin is observed in many patients withmalignant
tumors, contributing to the progress of cancer [16].
It is believed that in cancer patients, the level of TATI
increases along with the increase of the level of trypsin. So
far, there has not been an explanation of the mechanism of the
inhibitor’s action, TATI receptors have not been isolated, but it
is suggested that its aggressiveness is modulated by trypsin
activity. Thus, TATI expression recognized in the serum and in
the cancer tissue is a negative prognostic factor favoring the
spread of cancer [12].
In patients with endometrial cancer, there is an increase of
the level of TATI in the serum by approximately 21–57 %
compared to reference values. An increase of the TATI level
by 100 % in the serum occurs in patients with mucinous ovar-
ian cancer [17]. The sensitivity of TATI in patients with endo-
metrial cancer is estimated at approximately 31 % and its
specificity at 81 % [18].
The aim of the study is to compare the usefulness of the
determination of CEA and TATI in patients with endometrial
cancer in whom occurrence of recurrence or distant metastasis
of cancer was diagnosed in the course of observation after
treatment.
Material and method
Assessment of the level of CEA and TATI was carried out in
316 patients with endometrial cancer under observation in
1994–1995, who were treated according to staging as
determined in accordance with the then applicable FIGO clas-
sification from 1988. Subjects’ age ranges from 32 to 81, with
average age of 61, SD=8.72. Observation after treatment in
individual patients lasted from 4 months to 17 years. All pa-
tients with microscopically diagnosed negative prognostic
factors, i.e., deep infiltration of the uterus, poorly differentiat-
ed forms of cancer G2 and G3, spread in pelvic area after
primary surgery were treated with adjuvant radiotherapy and
hormone therapy, followed by post-treatment observation for
up to 17 years. Description of demographic variables and
clinical status is presented in Tables 1 and 2.
We analyzed the results of five determinations of both CEA
and TATI in serum, which were carried out (every 3–6 weeks)
before and after each stage of treatment—brachytherapy and
radiotherapy, and during the first three outpatient follow-up
visits taking place every 3 months after completion of treat-
ment. Assessment of the marker level was carried out within
5 months from the start of treatment, i.e., surgery.
In the course of the 17-year follow-up period, 59 (18 %)
patients were diagnosed with recurrent cancer and 68 (21 %)
with distant metastasis. Treatment failure appeared from
6 months to 11 years after completion of treatment.
The values of marker levels in patients with treatment fail-
ure ranged from 0 to 344 μg/l for CEA and from 0 to 876 μg/l
for TATI.
The paper presents the results of the relationship between
the observed levels of markers CEA and TATI and the occur-
rence of treatment failure (recurrence or distant metastases)
compared to a group to patients with successful treatment
outcomes. We analyzed the dynamics of changes in marker
levels in groups of persons with treatment failure after suc-
cessful treatment in order to create variables determining level
variations in these groups. For marker CEA, the variable
BCEA fluctuation in 5 measurements^ was created, and for
the marker TATI: Baverage TATI level.^ Non-parametric tests
were used because of the unfulfilled assumption of a normal
distribution of variables tested (Mann-Whitney test for inde-
pendent groups). Receiver operating characteristic (ROC)
curve analysis was also performed.
Results
Marker CEA level in patients in whom recurrence of the
disease was determined during observation already in the first
sample was significantly different from levels in patients in
whom there was no recurrence of cancer (Me=10 in the group
with recurrence, Me= 7 in the group without recurrence,
Mann-Whitney U test Z=−3.094, p=0.002). Full data from
all CEA level samples in patients depending on treatment
outcome is presented in Table 3.
The difference between marker CEA levels in groups with
and without recurrence was significant until the fourth sample
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(i.e., the first sample after finishing adjuvant treatment). Only
in the fifth sample, i.e., during the follow-up test after com-
pleted treatment (approximately 7th–8th month of the study),
the levels of markers CEA evened out and there was a signif-
icant drop in the level of the marker in the serum of patients
with recurrent disease, as shown in the data in Table 3 and
graphic chart in Fig. 1. In the same period, the marker level in
the group of patients without recurrence was relatively stable:
the median within 7–10 μg/l in five samples.
Table 4 shows the descriptive statistics of CEA levels in
patients with established disease recurrence and distant metas-
tasis. The calculations use the coefficient BCEA fluctuation in
5 measurements^—which is the difference between the max-
imum and minimum level of CEA in five subsequent samples.
“CEA fluctuation in 5 measurements”
¼ Max Ci i¼1;…5ð Þ‐Min Ci i¼1;…5ð Þ
Assessment of marker CEA showed that in patients with
recurrent disease, BCEA marker fluctuat ion in 5
measurements^ is significantly higher than in the group with-
out recurrence (Mann-Whitney Z=−4.910085, p=0.0000). In
the group without recurrence, the median of this variable is
7 μg/l (CI: (3.3; 10.7)); in the group with recurrence 14 μg/l
(CI: (0; 33.5).
Assessing CEA levels in patients with diagnosed distant
metastasis (meta), significantly greater fluctuations of CEA
levels were found in five measurements in the case of
metastasis (Mann-Whitney Z=−5.47668, p=0.0000). In the
group with metastasis, the median of CEA fluctuation in five
measurements is 15μg/l (CI: 0; 30.2) and in the group without
metastasis 7 μg/l (CI: (2.6; 11.4).
Assessing the second marker—TATI, significant differ-
ences in the level of the marker was observed in the first five
samples between the group with metastatic and the group
without metastasis, as well as between the group in which
recurrence occurred and the group with no recurrence. Results
of TATI levels in patients with recurrence and metastasis are
presented in Table 5 and Fig. 2. Therefore, the variable
Baverage TATI level^ was created, which is indicative of
changes in marker TATI levels in subsequent samples.
BAverage TATI level^ is the average of the first four samples
that were taken in the first 12 weeks from the start of the study.
Assessing the BAverage TATI level^ (Table 6) in patients
with recurrence, it was found that the average TATI level was
significantly higher compared with the cases in which there was
no recurrence (Mann-Whitney Z=−6.06653, p=0.00000). In
cases of recurrence, the median of the Baverage TATI level^
amounts to 28.25 (CI: 11.6; 44.9), and without recurrence, the
median is 12 μg/l. (CI: (8.4; 15.6)).
Similarly, the groups of patients with known metastasis
(META) and without metastasis differ significantly in their
average TATI level in the first four assays (Mann-Whitney
Z=−4.97475, p=0.000001). In patients diagnosed with dis-
tant metastasis (Table 5), the average level of TATI in the first
four samples was significantly higher, median of 22.1 μg/l
(Cl: (10.8; 33.4) compared with patients without metastasis,
median of 11.6 μg/l (Cl: (6.9; 16.4).
For TATI, the study of the correlation of dates in the
diagnosis of recurrence with the dates of marker determi-
nations showed the existence of a weak statistically signif-
icant correlation (r= 0.277, p= 0.035) of recurrence dates
with the dates of the second determination and a very
strong correlation (r= 0.730, p= 0.026) with the dates of
the fifth sample (during the first follow-up visit after treat-
ment). This fact may indicate that only few cases of recur-
rence were diagnosed from the second sample, more often
the recurrence was diagnose around the fifth sample. This
indicates a relatively late diagnosis of recurrence based on
other indicators than TATI.
ROC curve analysis was performed in order to examine the
extent to which the observed rapid increase of the levels of
markers CEA and TATI between samples determines recur-
rence and metastasis. Variables were defined for bothmarkers:
Table 2 Tables of the
number of variables
describing the clinical















Table 1 Descriptive statistics of
controlled variables Variable Average Median Min Max Standard deviation
Age 60.38 61.00 32.00 81.00 8.72
Observation time (years) 4.35 2.98 0.24 16.93 3.63
Time free from cancer (years) 3.44 2.26 0.00 16.44 3.60
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T3−1 ¼ T 3−T1T1 *100
Where
T3 means the level of marker TATI in the 3rd sample
T1 means the level of marker TATI in the 1st sample
and analogously
C3−1 ¼ C3−C1C1 *100
where
C3 means the level of marker CEA in the 3rd sample
C1 means the level of marker CEA in the 1st sample
The ROC curve, assessing the sensitivity and specificity of
CEA and TATI for the prognosis of recurrence, is presented in
Fig. 3.
Fig. 1 Graph of marker CEA levels in next five subsequent
determinations depending on recurrence
Table 3 Descriptive statistics of
CEA level in five determinations,
depending on the occurrence of
failures in treatment
Subsequent CEA samples 95%CI for Me Mann-Whitney U testa
Median −95%CI 95%CI Min Max Z p
Total N = 316
C_1 7 3.2 10.8 0 266
C_2 9 5.6 12.4 0 344
C_3 10 4.5 15.5 0 251
C_4 9 2.5 15.5 0 212
C_5 12 4.5 19.5 2 176
Recurrence no N= 257
C_1 7 4.8 9.2 0 134
C_2 8 6.1 9.9 0 112
C_3 9 5.4 12.6 0 176
C_4 8 5.4 10.6 0 65
C_5 10 1.3 18.7 2 176
Recurrence yes N= 59
C_1 10 0.0 27.7 1 266 −3.094 0.002
C_2 12 0.0 27.5 0 344 −3.251 0.001
C_3 16 0.0 36.8 0 251 −3.816 0.000
C_4 18 0.0 43.9 0 212 −3.342 0.001
C_5 12 3.8 20.2 7 40 −1.310 0.190
Meta no N= 248
C_1 7 4.2 9.8 0 233
C_2 8 6.0 10.0 0 87
C_3 9 2.6 15.4 0 251
C_4 8 0.5 15.5 0 212
C_5 9 7.3 10.7 2 21
Meta yes N = 69
C_1 8.5 0.0 22.8 0 266 −1.443 0.149
C_2 12 0.0 25.5 0 344 −3.462 0.001
C_3 14 3.2 24.8 0 176 −3.727 0.000
C_4 17 4.6 29.4 4 142 −4.190 0.000
C_5 20.5 0.0 42.9 3.7 176 −3.429 0.001
aMann-Whitney U test was used to compare the results of CEA level samples between groups of cured patients
with patients with treatment failure (recurrence or distant metastasis)
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Based on the ROC curve analysis, it was found that if there
was an increase in CEA levels by more than 20 % in the third
sample compared to the first sample, then cancer recurrence
was diagnosed in 75.9 % of cases. Thus, the sensitivity of
CEA used to determine recurrence is 76 %. Specificity, or
ability to detect patients without recurrence, is 54.3 %, which
is quite low. Similarly, in the analysis of ROC curves for
evaluation of the occurrence of metastasis based on changes
in CEA levels in the third and first sample, it was found that
the sensitivity and specificity is low, respectively 69.7 and
53.8 %.
Using the ROC curve analysis (Fig. 3), it was found that if
the marker TATI level in the third sample exceeds by 10.6 %
the output level, in 84.4% (sensitivity) of the cases, this means
the occurrence of recurrence and in 75.7 % (specificity), the
occurrence of metastasis. Marker TATI turns out to be a very
sensitive indicator signaling the possibility of recurrence ear-
lier than other traditional methods of diagnosis of recurrence
in patients with endometrial cancer.
Table 5 Descriptive statistics of
TATI levels from five samples in
patients with treatment failure
Subsequent TATI samples 95%CI for Me Mann-Whitney U test*
Median −95%CI 95%CI Min Max Z p
Total N = 316
T_1 16 11.5 20.5 2 302
T_2 15 10.5 19.5 0 334
T_3 17 3.9 30.1 2 876
T_4 17 2.0 32.0 1 543
T_5 17.5 10.3 24.7 5 87
Recurrence no N= 257
T_1 15 10.2 19.8 2 302
T_2 14 10.1 17.9 0 221
T_3 15 6.5 23.5 2 451
T_4 16 6.7 25.3 1 329
T_5 16 10.1 21.9 5 87
Recurrence yes N= 59
T_1 19 6.8 31.2 7 231 −2.160 0.031
T_2 21 4.8 37.2 0 334 −4.089 0.000
T_3 34 0.0 84.3 5 876 −5.694 0.000
T_4 43 0.0 98.1 7 543 −5.170 0.000
T_5 57 35.0 79.0 6 84 −3.028 0.002
Meta no N= 248
T_1 15 10.1 19.9 2 290
T_2 14 9.5 18.5 0 334
T_3 15 0.0 30.4 2 876
T_4 16 0.0 33.7 1 543
T_5 15 7.7 22.3 5 87
Meta yes N = 69
T_1 19 7.7 30.3 7 302 −1.972 0.049
T_2 22 9.5 34.5 0 221 −4.316 0.000
T_3 27 2.5 51.5 5 451 −4.643 0.000
T_4 29 1.4 56.6 10 329 −4.613 0.000
T_5 29.5 15.7 43.3 10 84 −3.941 0.000
Table 4 Assessment of the fluctuations of CEA levels in five
measurements in patients depending on treatment failure
Fluctuation of CEA in 5 measurements 95%CI for Me
N Median −95%CI 95%CI Min Max
Recurrence
No 258 7 3.3 10.7 0 164
Yes 59 14 0.0 33.5 1 261
Meta
No 248 7.0 2.6 11.4 0 237
Yes 69 15.0 0.0 30.2 0 261
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Discussion
Endometrial cancer patients are a group of patients with a lack
of sufficiently sensitive and specific markers correlated with
the diagnosis of the disease and with its course.
CEA is one of the markers investigated most frequently
and for the longest period of time in case of patients with
cancer in different locations. It was tested in order to deter-
mine its usefulness in the early diagnosis of endometrial can-
cer alongside such markers as SCC (squamous cell carcinoma
antigen), CYFRA 21-1 (Cytokeratin 19 fragments), CA 125
(cancer antigen-125), CA 19-9 (cancer antigen-19-9), or IAP
(immunosuppressive acidic protein). However, none of them
was recognized by the experts as relevant, i.e., sufficiently
sensitive and specific in the diagnosis and prognosis of the
course of endometrial cancer.
The increase in the level of the CEA antigen in serum was
found in a small group of patients (14–22%) with endometrial
cancer [19]. Bruns et al. observed that it is present only in
6.3 % of patients in the early stage endometrial cancer and
not much more often, because in 20 % of patients, in the
advanced stages of the disease [20].
The increase in the value of CEA was also used to differ-
entiate adenocarcinoma derived from the uterus and the cer-
vix. Castrillon et al. showed that CEA and vimentin (VIM) are
markers that allow to distinguish between cervical cancer and
endometrial cancer. Higher values of CEA have been reported
more often in patients with cervical cancer, in 62–96 % of
cases, and less often in patients with endometrial cancer, in
27–70 % of cases [21, 22].
The highest diagnostic value of CEAwas demonstrated for
the tumors of the colon and rectum. According to some au-
thors, the increase in CEA levels (>20 ng/ml) is correlated
with the degree of advancement of colon cancer and is the
higher the greater the progress of the disease [23]. An increas-
ing level of CEA in the blood serum may be associated with
the development of cancer and is the first sign of recurrence in
about 50 % of patients in whom the tumor was surgically
removed [24, 25].
In the recommendations of the American Society of Clin-
ical Oncology (ASCO), National Academy of Clinical Bio-
chemistry (NACB), and the European Group on Tumor
Markers (EGTM), determination of CEA is recommended
after surgical removal of the tumor in patients with colorectal
cancer every 2–3 months for at least 3 years, for the early
detection of recurrence or metastasis. However, these recom-
mendations lack the guidelines defining the scope of changes
in the level of the marker that would be considered clinically
significant. EGTM proposed to consider an increase in the
level of the marker in relation to the previous tests of at least
30 % as significant [23, 26].
CEA was also one of the first markers assayed in patients
with breast cancer, but now, due to its low sensitivity and
specificity, the National Academy of Clinical Biochemistry
(NACB) and the European Group on Tumor Markers
(EGTM) do not recommend its determination in these patients
[27, 28]. However, the build-up of CEA levels is observed in
breast cancer patients with more advanced disease, and its
elevated values prior to treatment are not considered to be an
important prognostic factor [29, 30].
Our study analyzed the value of CEA in patients with en-
dometrial cancer with post-treatment recurrence or metastasis.
Evaluation of usefulness of the marker was based on the anal-
ysis of its five determinations within 18 weeks of treatment
and during the first three follow-up tests after the completion
of treatment. Comparingmarker levels in cured patients and in
patients with current recurrence or metastasis, it was found
that CEA is a quite sensitive (75.9 %) indicator for predicting
recurrence and a weaker (sensitivity 69.7 %) indicator for
predicting the occurrence of metastasis in patients with endo-
metrial cancer. Serial arrays of CEA conducted over a period
of 5 months after treatment also showed, in case of colorectal
cancer patients, a high sensitivity of 80 % and specificity of
70 % for the early detection of recurrence and metastasis in
these patients [31, 32].
In our study, the specificity of CEA for the detection of
recurrence and metastasis was low, respectively 54.3 and
53.8 %. The second marker evaluated in patients with
Fig. 2 Graph of marker TATI levels in next five subsequent
determinations depending on recurrence
Table 6 Assessment of the average level of marker TATI in patients
depending on treatment failure
Average TATI level 95%CI for Me
N Median −95%CI 95%CI Min Max
Recurrence
No 257 12 8.4 15.6 2.25 243.5
Yes 59 28.25 11.6 44.9 4 269.5
Meta
No 248 11.6 6.9 16.4 2.25 269.5
Yes 68 22.1 10.8 33.4 2.25 243.5
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endometrial cancer was pancreatic trypsin inhibitor TATI,
which is a marker assessed extremely rarely. Originally, its
elevated levels were attributed only to diseases of the pancreas
and liver. This marker was considered more useful in the di-
agnosis of bladder cancer than previously identified markers
TPA (tissue polypeptide antigen), CEA or SCC (squamous
cell carcinoma antigen). TATI levels increase with the prog-
ress of bladder cancer in 20–70 % of patients [33, 34].
In patients with prostate, breast, colon, and lung cancer,
and even in patients with endometriosis, high sensitivity of
TATI assays was observed, which increases with the progress
of the disease [35–37].
TATI expression in patients with endometrial cancer with
current negative prognostic factors, i.e., lymph node metasta-
sis, infiltration of the cervical canal, or ovarian metastases
observed in the histological evaluation after the removal of
the reproductive organs, did not differ from the level of the
inhibitor in patients in whom these characteristics were not
present [38].
In contrast, observation of TATI levels in patients with
treatment failures showed that it is more sensitive (84.4 vs
54.3 %) than CEA as an indicator of recurrence of endo-
metrial cancer and a better indicator than CEA (sensitivity
75.7 vs 53.8 %) for the occurrence of distant metastasis
[39].
In the light of the study, it appears that the occurrence of
recurrence or metastasis may already be suspected in case a
significant increase of TATI levels in the first assessment after
completed treatment, i.e., in its fourth assessment. If there is
an increase in the marker TATI level in the fourth sample by
274 % compared to the first value of its assessment, we can
expect cancer recurrence, and in case of a slightly smaller
increase of TATI—by 248 %, we should expect distant me-
tastases. Assessment of TATI seems to be a more sensitive
indicator of treatment failure than assessment of CEA.
Conclusions
1. The average of four samples of TATI levels taken within
18 weeks is a sensitive indicator signaling the 84.4 %
possibility of recurrence earlier than other traditional
methods and a fairly good indicator of 75.7 % chance of
distant metastasis.
2. Sensitivity of CEA level fluctuations for the assessment of
cancer recurrence and metastasis is low, and amounts to,
respectively 75.9 %, and specificity 54.3 % and 69.7 %,
specificity 53.8 %.
3. Correlation of the dates of recurrence is indeed very high
with the date of the fifth sample, i.e., during the first ex-
amination after completion of treatment.
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